Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis

被引:26
|
作者
Liu, Shuo [1 ,2 ]
Chung, Melody P. [3 ]
Ley, Brett [1 ]
French, Sarah [4 ]
Elicker, Brett M. [5 ]
Fiorentino, David F. [6 ]
Chung, Lorinda S. [7 ]
Boin, Francesco [8 ]
Wolters, Paul J. [1 ]
机构
[1] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Sleep Med, Dept Med, San Francisco, CA 94143 USA
[2] China Med Univ, Pulm & Crit Care Med, Affiliated Hosp 4, Shenyang, Liaoning, Peoples R China
[3] Stanford Univ, Div Rheumatol & Immunol, Sch Med, Stanford, CA USA
[4] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA USA
[5] Univ Calif San Francisco, Div Radiol, San Francisco, CA 94143 USA
[6] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA USA
[7] Stanford Univ, Div Rheumatol & Immunol, Dept Dermatol, Sch Med, Stanford, CA USA
[8] Cedars Sinai Med Ctr, Div Rheumatol, Dept Med, Los Angeles, CA USA
基金
中国国家自然科学基金;
关键词
systemic disease and lungs; interstitial fibrosis; rare lung diseases; connective tissue disease associated lung disease; IDIOPATHIC PULMONARY-FIBROSIS; OBSERVATIONAL COHORT; MORTALITY; SURVIVAL; MARKER;
D O I
10.1136/thoraxjnl-2020-215918
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Peripheral blood leucocyte telomere length (PBL-TL) is associated with outcomes in patients with idiopathic pulmonary fibrosis. Whether PBL-TL is associated with progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is unknown. Methods A retrospective observational cohort study was performed using prospectively collected data from 213 patients with SSc followed at the University of California San Francisco (UCSF) Scleroderma Center. PBL-TL was measured by quantitative PCR of DNA isolated from peripheral blood. Associations between PBL-TL and pulmonary function test trends in patients with SSc-ILD were assessed by longitudinal analysis using Generalised Linear Mixed Models. Findings were validated in a cohort of 61 patients with SSc-ILD enrolled in the Stanford University Scleroderma Center database. Results Patients with UCSF SSc with ILD were found to have shorter PBL-TL compared with those without ILD (6554 +/- 671 base pairs (bp) vs 6782 +/- 698 bp, p=0.01). Shorter PBL-TL was associated with the presence of ILD (adjusted OR 2.1 per 1000 bp TL decrease, 95% CI [1.25 to 3.70], p=0.006). PBL-TL was shorter in patients with SSc-ILD lacking SSc-specific autoantibodies compared with seropositive subjects (6237 +/- 647 bp vs 6651 +/- 653 bp, p=0.004). Shorter PBL-TL was associated with increased risk for lung function deterioration with an average of 67 mL greater loss in per year for every 1000 bp decrease in PBL-TL in the combined SSc-ILD cohorts (longitudinal analysis, adjusted model: 95% CI -104 mL to -33 mL, p<0.001). Conclusions These findings suggest that telomere dysfunction may be associated with SSc-ILD progression and that PBL-TL measurement may be useful for stratifying risk for SSc-ILD progression.
引用
收藏
页码:1186 / 1192
页数:7
相关论文
共 50 条
  • [41] Genetic Susceptibility to Interstitial Lung Disease Associated with Systemic Sclerosis
    Tochimoto, Akiko
    Kawaguchi, Yasushi
    Yamanaka, Hisashi
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2015, 9 : 135 - 140
  • [42] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2518 - 2528
  • [43] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303
  • [44] Management of Systemic-Sclerosis-Associated Interstitial Lung Disease
    Silver, Katherine Culp
    Silver, Richard M.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (03) : 439 - +
  • [45] Experience with azathioprine in systemic sclerosis associated with interstitial lung disease
    Dheda, K
    Lalloo, UG
    Cassim, B
    Mody, GM
    CLINICAL RHEUMATOLOGY, 2004, 23 (04) : 306 - 309
  • [46] Treatment for systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Lescoat, Alain
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
  • [47] Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
    Donio, Patrick
    Fidler, Wesley
    Diaz-Martinez, Juan Pablo
    Bangert, Elvira
    Ahmad, Zareen
    Soowamber, Medha
    Johnson, Sindhu
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1303 - 1304
  • [48] Breathomics to monitor interstitial lung disease associated with systemic sclerosis
    Massenet, Thibault
    Potjewijd, Judith
    Tobal, Rachid
    Gester, Fanny
    Zanella, Delphine
    Henket, Monique
    Njock, Makon-Sebastien
    Dejong, Thibaut
    Gridelet, Gregory
    Giltay, Laurie
    Guissard, Francoise
    Andre, Beatrice
    Ribbens, Clio
    Louis, Renaud
    Van Paassen, Pieter
    Guiot, Julien
    Stefanuto, Pierre-Hugues
    ERJ OPEN RESEARCH, 2024, 10 (04)
  • [49] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (11): : E755 - E755
  • [50] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Rahimi, Susan
    LANCET RESPIRATORY MEDICINE, 2020, 8 (02): : 136 - 136